Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537923 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,428
- Enrollment target
NCT04537923 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,428 participants.
The verdict
NCT04537923, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,428 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Interventions
- DRUG Tirzepatide
- DRUG Insulin Lispro (U100)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,428 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537923
The ClinicalTrials.gov registry entry for NCT04537923 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT04537923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537923 about?
NCT04537923 is a clinical study titled "A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin". The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
What is the current status of trial NCT04537923?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,428 participants. The study started on 2020-10-19. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04537923?
The interventions under investigation include: Tirzepatide (DRUG), Insulin Lispro (U100) (DRUG).
Who is sponsoring clinical trial NCT04537923?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.